Trevi Therapeutics Inc 2025年度报告

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YesշNoն Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filingrequirements for the past 90 days. YesշNoն Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).Yes⌧No… Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. Large accelerated filerնNon-accelerated filerշEmerging growth companyն Smaller reporting companyշ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any newor revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.ն Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internalcontrol over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm thatprepared or issued its audit report.ն If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in thefiling reflect the correction of an error to previously issued financial statements.ն Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation receivedby any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).ն Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesնNoշ As of June 30, 2025, the last business day of the Registrant’s most recently completed second fiscal quarter, the aggregate market value of the voting andnon-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on The Nasdaq StockMarket, was $588.4 million.The number of shares of the Registrant’s Common Stock outstanding as of March 12, 2026 was 128,397,271. DOCUMENTS INCORPORATED BY REFERENCEPortions of the Proxy Statement for the registrant’s 2026 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA This Annual Report on Form 10-K contains forward-looking statements that involve substantial risks anduncertainties. All statements, other than statements of historical fact, contained in this Annual Report on Form 10-K,including statements regarding our strategy, future operations, future financial position, future revenues and profitability,projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,”“believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,”“should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements, although not allforward-looking statements contain these identifying words. The forward-looking statements in this Annual Report on Form 10-K include, among other things, statements about: •our plans to develop and, if approved, subsequently commercialize Haduvio for the treatment of chronic cough inpatients with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractorychronic cough, or RCC; •our clinical trials, including our planned Phase 3 trials of Haduvio for the treatment of chronic cough in patients withIPF, our planned adaptive design Phase 2b clinical trial of Haduvio for the treatment of chronic cough in patients withnon-IPF ILD, our planned Phase 2b trial of Haduvio for the treatment of patients with RCC, and our planned Phase 1NDA supportive studies;•our expectations regarding the timing for the initiation of clinical trials and the reporting of data from such trials;•the timing of and our ability to submit applications for and to obtain and maintain regulatory approvals for Haduvio;•our expectations regarding our ability to fund our operating expenses, includin